Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18780132 | Aminopyrimidine Derivatives as Cyclin-Dependent Kinase Inhibitors | July 2024 | January 2025 | Allow | 6 | 0 | 0 | Yes | No |
| 18192703 | ABIETANES AND METHODS OF MAKING AND USING THE SAME | March 2023 | December 2024 | Allow | 21 | 1 | 0 | Yes | No |
| 18189380 | SULFONAMIDO DERIVATIVES AS CYCLIN-DEPENDENT KINASE 2 INHIBITORS | March 2023 | February 2025 | Allow | 23 | 0 | 1 | Yes | No |
| 18184335 | IKAROS ZINC FINGER FAMILY DEGRADERS AND USES THEREOF | March 2023 | February 2025 | Allow | 23 | 1 | 0 | No | No |
| 18181965 | 2-AMINOTHIAZOLES DERIVATIVES AND METHOD OF PREPARATION THEREOF USING SUPER-PARAMAGNETIC IRON OXIDE NANOPARTICLES (SPIONS) | March 2023 | January 2025 | Allow | 23 | 1 | 1 | No | No |
| 18173426 | COMPOUNDS AS GLP-1R AGONISTS | February 2023 | March 2025 | Allow | 25 | 1 | 1 | Yes | No |
| 17998546 | Piperazine Cyclic Ureas | November 2022 | June 2025 | Allow | 31 | 0 | 0 | Yes | No |
| 17895273 | 2,3-DISUBSTITUTED 1-ACYL-4-AMINO-1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES AND THEIR USE AS BROMODOMAIN INHIBITORS | August 2022 | March 2025 | Allow | 31 | 0 | 0 | No | No |
| 17786295 | TETRAHYDROBENZO-QUINOLINE SULFONAMIDES DERIVATIVE COMPOUNDS | June 2022 | May 2025 | Allow | 35 | 0 | 0 | Yes | No |
| 17663716 | COMPOUNDS | May 2022 | April 2025 | Allow | 35 | 0 | 1 | Yes | No |
| 17764658 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | March 2022 | January 2025 | Allow | 34 | 0 | 0 | No | No |
| 17638741 | BENZIMIDAZOLE AND HYDROGENATED CARBAZOLE DERIVATIVES AS GPX4 INHIBITORS | February 2022 | May 2025 | Abandon | 39 | 0 | 1 | No | No |
| 17637860 | PYRAZOLE DERIVATIVES AND USE THEREOF | February 2022 | January 2025 | Allow | 34 | 0 | 0 | Yes | No |
| 17675917 | N2,N4-DIPHENYLPYRIMIDINE-2,4-DIAMINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF CANCER | February 2022 | May 2025 | Abandon | 39 | 1 | 0 | No | No |
| 17633209 | 5-HETEROARYL-PYRIDIN-2-AMINE COMPOUNDS AS NEUROPEPTIDE FF RECEPTOR ANTAGONISTS | February 2022 | May 2025 | Abandon | 40 | 0 | 1 | No | No |
| 17632132 | 1H-[1, 2, 3]TRIAZOLO[4, 5-H] QUINAZOLINE COMPOUNDS ACTING AS PROTEIN KINASE INHIBITORS | February 2022 | January 2025 | Allow | 36 | 1 | 0 | No | No |
| 17577949 | PHARMACEUTICAL FORMULATIONS, PROCESSES FOR PREPARATION, AND METHODS OF USE | January 2022 | June 2025 | Abandon | 41 | 1 | 0 | No | No |
| 17620782 | BICYCLIC HETEROCYCLIC COMPOUNDS AS INHIBITORS OF BCDIN3D ACTIVITY | December 2021 | April 2025 | Abandon | 40 | 0 | 1 | No | No |
| 17618767 | INDAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL APPLICATION THEREOF | December 2021 | February 2025 | Allow | 38 | 0 | 1 | Yes | No |
| 17615821 | PROSTAGLANDIN E2 RECEPTOR 4 ANTAGONISTS AND USES THEREOF | December 2021 | May 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17613221 | MESYLATE SALT OF PARA-TOPOLIN, COMPOSITIONS CONTAINING SAID SALT AND USE THEREOF | November 2021 | March 2025 | Allow | 40 | 1 | 1 | Yes | No |
| 17609989 | SUBSTITUTED 1-AMINO-1H-IMIDAZOLE-5-CARBOXAMIDE AS BRUTON'S TYROSINE KINASE INHIBITORS | November 2021 | January 2025 | Allow | 38 | 0 | 1 | Yes | No |
| 17608524 | PREPARATION FOR USE IN WEIGHT MANAGEMENT COMPRISING OMEGA-3 FATTY ACID SALTS AND BASIC AMINO ACIDS | November 2021 | March 2025 | Abandon | 40 | 1 | 0 | No | No |
| 17608459 | COMPOUNDS INHIBITING TDG ACTIVITY | November 2021 | March 2025 | Abandon | 40 | 0 | 1 | No | No |
| 17605808 | GINKGOLIDE B DERIVATIVE AND SALT THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF | October 2021 | April 2025 | Allow | 42 | 1 | 1 | Yes | No |
| 17604606 | METHODS OF TREATING NEUROCOGNITIVE DISORDERS, CHRONIC PAIN AND REDUCING INFLAMMATION | October 2021 | March 2025 | Allow | 41 | 1 | 0 | Yes | No |
No appeal data available for this record. This may indicate that no appeals have been filed or decided for applications in this dataset.
Examiner KUCKLA, ANNA GRACE works in Art Unit 1626 and has examined 25 patent applications in our dataset. With an allowance rate of 68.0%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 38 months.
Examiner KUCKLA, ANNA GRACE's allowance rate of 68.0% places them in the 22% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by KUCKLA, ANNA GRACE receive 0.44 office actions before reaching final disposition. This places the examiner in the 3% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.
The median time to disposition (half-life) for applications examined by KUCKLA, ANNA GRACE is 38 months. This places the examiner in the 11% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +61.5% benefit to allowance rate for applications examined by KUCKLA, ANNA GRACE. This interview benefit is in the 98% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.